02295nas a2200385   4500000000100000008004100001260003000042653003400072653001700106653002000123653003200143100001800175700001800193700001600211700001400227700001500241700001600256700001500272700001700287700001700304700001400321700001200335700001800347700001500365700001600380700001800396700001600414700001500430245015500445856026000600300001400860490000700874520100300881022002501884       2025                            d  c12/2025bEverant Journals10aLepromatous leprosy diagnosis10aTuberculosis10aDiagnostic test10aHermatologic Manifestations1 aGonzález JFM1 aGonzález ALR1 aGamiño AED1 aLópez LC1 aMoreno FAR1 aGarcía AVP1 aSanchez MN1 aMontalvo CMG1 aEsquivel KGS1 aLópez MA1 aRomo AC1 aRodríguez JG1 aBasurto IN1 aHerrera SRE1 aMartínez MJS1 aVelasco KTG1 aDurón AXM00aConcurrent Lepromatous Leprosy and Active Tuberculosis in A Young Male: A Complex Diagnostic and Therapeutic Challenge with Hematologic Manifestations  uhttps://www.researchgate.net/publication/399198549_Concurrent_Lepromatous_Leprosy_and_Active_Tuberculosis_in_A_Young_Male_A_Complex_Diagnostic_and_Therapeutic_Challenge_with_Hematologic_Manifestations/fulltext/695429bc27359023a011d2ab/Concurrent-Lepromato  a2058-20620 v053 a<jats:p>This report details the clinical evolution of a 23-year-old male presenting with the exceptionally rare co-occurrence of active lepromatous lerosy and tuberculous lymphadenitis, complicated by severe immune thrombocytopenia. The patient’s presentation—spanning chronic dermatological findings, acute systemic symptoms, and profound hematological disturbance—required a multifaceted diagnostic approach culminating in histopathological and microbiological confirmation of both mycobacterial infections. Management was successfully integrated, utilizing a single rifampin-based antitubercular regimen to simultaneously address both diseases, resulting in resolution of thrombocytopenia and significant clinical improvement. This case highlights the diagnostic complexity in co-endemic regions, the potential for tuberculosis to drive significant parainfectious hematologic complications, and the feasibility of a unified pharmacological strategy for dual mycobacterial disease.</jats:p>  a2767-8326, 2767-8342